Trials / Terminated
TerminatedNCT00272909
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This research study is designed to evaluate the safety, tolerability, and efficacy of SUN N4057 (piclozotan) in subjects with acute ischemic stroke within 9 hours of the onset of symptoms.
Detailed description
The primary objective of the study is to determine the efficacy of a 72 hour infusion of SUN N4057 (piclozotan) in subjects with clinical findings of an acute ischemic stroke and a magnetic resonance imaging (MRI) demonstrating a measurable penumbra (perfusion-weighted imaging \[PWI\] minus diffusion-weighted imaging \[DWI\] volume). Efficacy will be determined by comparing the proportion of subjects with no growth in stroke lesion volume as assessed by DWI at Screening to stroke lesion volume assessed by FLAIR (fluid-attenuated inversion recovery) on Day 28 in the piclozotan group versus the placebo group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | piclozotan low dose | Continuous IV infusion over a period of up to 72 hours of piclozotan |
| DRUG | placebo | Continuous IV infusion over a period of up to 72 hours of placebo. |
| DRUG | piclozotan high dose | Continuous IV infusion over a period of up to 72 hours of piclozotan |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2006-10-01
- Completion
- 2007-01-01
- First posted
- 2006-01-09
- Last updated
- 2015-10-20
Locations
47 sites across 7 countries: United States, Belgium, Germany, Israel, Poland, South Africa, Spain
Source: ClinicalTrials.gov record NCT00272909. Inclusion in this directory is not an endorsement.